Cell Therapeutics, Ready To Tap Financing (CTIC)

Print Email

Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million.  This will allow it to sell debt securities, common stock, preferred stock, and warrants. 

Last Tuesday, the company announced progress in beginning Phase III testing for its non-Hodgkin’s lymphoma treatment. Friday, the company filed its annual report.

Shares have showed no reaction to the filing, with a 0% change, sitting at $0.66.  The 52-week range is $0.47 to $7.56 and its current market cap is only $62.5 million.

Rachel Lopez
March 31, 2008